search tools

New Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the Treatment of Cancers Deficient ...

Edit Stockhouse 06 Jun 2016
New Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers ... J. Med ... arthritis (1.6%), exfoliative dermatitis, bullous pemphigoid, uveitis, myositis, Guillain-Barré syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising in a patient with inflammatory foci in brain parenchyma....

KEYTRUDA® (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates ...

Edit Stockhouse 06 Jun 2016
Findings Support Initiation of Phase 3 Pivotal Study (KEYNOTE-204) Evaluating KEYTRUDA Versus Brentuximab Vedotin in Relapsed or Refractory cHL ... CDT (Location ... CDT (Location ... arthritis (1.6%), exfoliative dermatitis, bullous pemphigoid, uveitis, myositis, Guillain-Barré syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising in a patient with inflammatory foci in brain parenchyma ... Merck ... or....

KEYTRUDA® (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087 (Merck & Co Inc)

Edit Public Technologies 06 Jun 2016
(Source. Merck & Co Inc) ... These data will be presented today at the 52 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 8.00 - 11.30 a.m. CDT (Location ... arthritis (1.6%), exfoliative dermatitis, bullous pemphigoid, uveitis, myositis, Guillain-Barré syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising in a patient with inflammatory foci in brain parenchyma....

Updated Findings from KEYNOTE-012 for KEYTRUDA® (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent or Metastatic Head and Neck Cancer (Merck & Co Inc)

Edit Public Technologies 06 Jun 2016
(Source. Merck & Co Inc) ... Data are being presented at the 52 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago ... The U.S ... CDT (Location. S100bc) ... CDT (Location ... arthritis (1.6%), exfoliative dermatitis, bullous pemphigoid, uveitis, myositis, Guillain-Barré syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising in a patient with inflammatory foci in brain parenchyma....

New Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers (Merck & Co Inc)

Edit Public Technologies 05 Jun 2016
(Source. Merck & Co Inc). KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE ... Updated Findings from Non-Colorectal Cancer Cohort (Abstract #3003)and Colorectal Cancer Cohort (Abstract #103) ... arthritis (1.6%), exfoliative dermatitis, bullous pemphigoid, uveitis, myositis, Guillain-Barré syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising in a patient with inflammatory foci in brain parenchyma....

New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting (Merck & Co Inc)

Edit Public Technologies 05 Jun 2016
(Source. Merck & Co Inc) ... Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories ... Findings from MASTERYKEY-265 ... arthritis (1.6%), exfoliative dermatitis, bullous pemphigoid, uveitis, myositis, Guillain-Barré syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising in a patient with inflammatory foci in brain parenchyma ... Inc....

First signalling pathway of the digestive lineage in planarians is described (Universitat de Barcelona)

Edit Public Technologies 20 May 2016
(Source. Universitat de Barcelona). Planarian Schmidtea mediterranea is a traditional model to study cell regeneration, organogenesis, body symmetry patterns and stem cell regulation ... 20/05/2016. Recerca ... EGFR pathway ... That means, planaria cannot regenerate nor maintain the digestive system and that happens because the progenitors cannot completely differentiate and they amass in the parenchyma out of the digestive system' say the authors....

New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting (Merck & Co Inc)

Edit Public Technologies 18 May 2016
(Source. Merck & Co Inc) ... These data will be presented at the 52 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3 - 7, 2016 ... CDT (Location ... arthritis (1.6%), exfoliative dermatitis, bullous pemphigoid, uveitis, myositis, Guillain-Barré syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising in a patient with inflammatory foci in brain parenchyma ... Inc....

New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, ...

Edit Stockhouse 18 May 2016
New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting ... CDT (Location ... arthritis (1.6%), exfoliative dermatitis, bullous pemphigoid, uveitis, myositis, Guillain-Barré syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising in a patient with inflammatory foci in brain parenchyma....

New KEYTRUDA® (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated Findings in Head and Neck Cancer (Merck & Co Inc)

Edit Public Technologies 16 May 2016
(Source. Merck & Co Inc). KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE ... EDT ... Roy Baynes, senior vice president and head of global clinical development, Merck Research Laboratories ... C ... J ... arthritis (1.6%), exfoliative dermatitis, bullous pemphigoid, uveitis, myositis, Guillain-Barré syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising in a patient with inflammatory foci in brain parenchyma....

Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1) (Dicerna Pharmaceuticals Inc)

Edit Public Technologies 13 May 2016
(Source. Dicerna Pharmaceuticals Inc) 7229bc1c-e61b-49e4-831b-66dbbfdb5134.pdf. May 13, 2016 Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1). Milestone for DsiRNA Therapeutic Follows Receipt of Orphan Drug Designation in US and EU ... 4.2 and 11.5 years, depending on whether nephrocalcinosis (calcification in the renal parenchyma, the functional part of the....

Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL) (Merck & Co Inc)

Edit Public Technologies 18 Apr 2016
(Source. Merck & Co Inc). KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE.MRK), known as MSD outside the United States and Canada, today announced that the U.S ... Roger M ... arthritis (1.6%), exfoliative dermatitis, bullous pemphigoid, uveitis, myositis, Guillain-Barré syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising in a patient with inflammatory foci in brain parenchyma ... About Merck ... Inc....

FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Recurrent or Metastatic Head and Neck Cancer, and Grants Priority Review (Merck & Co Inc)

Edit Public Technologies 13 Apr 2016
(Source. Merck & Co Inc). KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE. MRK), known as MSD outside the United States and Canada, today announced that the U.S ... In the U.S ... arthritis (1.6%), exfoliative dermatitis, bullous pemphigoid, uveitis, myositis, Guillain-Barré syndrome, myasthenia gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising in a patient with inflammatory foci in brain parenchyma ... About Merck....
×
×
×
×